Celtaxsys begins patient enrolment for first clinical study of cystic fibrosis drug

US-based clinical stage drug discovery and development firm Celtaxsys has started enrolling patients for its first trial of its lead clinical stage drug candidate, CTX-4430, to treat patients with cystic fibrosis (CF) lung disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news